Archive: 18/08/2016

Brivaracetam in epilepsy: Added benefit still not proven

Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adults and adolescents from 16 years of age with epileptic seizures. The German Institute for Quality and Efficiency in Health ...

Ramucirumab in stomach cancer: Added benefit not proven

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...

page 3 from 7